real-time news and commentary for investors
Tuesday, Sep 24
Bristol-Myers Squibb and AstraZeneca report Phase III dapagliflozin data
- Bristol-Myers Squibb (BMY) and AstraZeneca's (AZN) SGLT2 inhibitor dapagliflozin helped improve HbA1c levels when used as an add-on therapy to metformin plus sulfonylurea.
- Patients taking dapagliflozin also saw "significant improvements" in fasting plasma glucose and body weight at 24 weeks.
- The drug works independently of insulin and is approved for the treatment of type 2 diabetes in Europe, Australia, Brazil, Mexico and New Zealand.
- PDUFA date is January 11, 2014. (PR)